Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Comparative miRNA-Based Fingerprinting Reveals Biological Differences in Human Olfactory Mucosa- and Bone-Marrow-Derived Mesenchymal Stromal Cells.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML.
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.
Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis.
Rituximab product approval information - Licensing action
Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci.
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
NOVANTRONE. mitoXANTRONE for injection concentrate
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Inosine, an Endogenous Purine Nucleoside, Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis: a Role for A2A Adenosine Receptor.
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
Current and future immunotherapy targets in autoimmune neurology.
U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R)
Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy.
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
A case of multiple evanescent white dot syndrome misdiagnosed as optic neuritis: Differential diagnosis for the neurologist.
Dimethyl Fumarate Inhibits the Nuclear Factor kappaB Pathway in Breast Cancer Cells by Covalent Modification of p65.
Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis.
Alemtuzumab for the Treatment of Multiple Sclerosis
PML in a patient treated with fumaric acid.
Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion.
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.

Pages